Transforming Molecular Diagnostics through NanoTechnology

Informacje na temat projektu

UbiHealth

Identyfikator umowy o grant: 101188322

DOI

10.3030/101188322

Data podpisania przez KE 20 Listopada 2024

Data rozpoczęcia 1 Grudnia 2024

Data zakończenia 30 Listopada 2026

Finansowanie w ramach

• The European Innovation Council (EIC)

Koszt całkowity

Brak danych

Wkład UE

€ 2 499 999,00

Koordynowany przez

ALTRATECH LIMITED
Ireland

Periodic Reporting for period 1 - UbiHealth (Transforming Molecular Diagnostics through NanoTechnology)

Okres sprawozdawczy: 2024-12-01 do 2025-11-30

Podsumowanie kontekstu i ogólnych celów projektu

Project Summary
Altratech introduce a completely new method of molecular detection. This is a first-of-kind, multianalyte DNA, RNA, antibody and antigen diagnostic. It delivers concurrent serology and nucleic acid detection. The technology is compliant with the challenging demands of WHO REASSURED criteria, especially in providing a commercially viable diagnostic tool for the developing world.
The innovation is in the process of being productised by our sub-contractor The Cambridge Design Partnership (UK) into a fully automated, portable, stand-alone instrument for Point of Care and Point of Need. It will not require medically qualified personnel to operate. This innovation provides substantial advantages over existing, more complex, expensive and less portable Point of Care systems for the management of viral infections such as HIV, Hepatitis, Influenza, Malaria, Meningitis, Shingles, Dengue Fever, HPV, EBV-related cancers, and many more.
The Value Proposition to our target customers, who will be the world’s leading diagnostic companies, is the ability to licence a novel patent protected product, with a wider range of market applications compared to their current diagnostic products. This will facilitate their entry into new markets and increase gross margins in existing markets. This innovation will impact the €48B Diagnostics industry.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

•Isothermal (Recombinase Polymerase Amplification) protocol developed, detecting down to 1000 copies/mL from whole blood, and four other concentrations from whole blood and plasma.
•A filtration system provided a practical method of plasma separation and using this workflow, reliably detected HIV RNA at 1,000 copies/mL on the Altratech CMOS chip cartridge.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

Altratech Detection Cartridge showed greater sensitivity than gold-standard optical detection at very low copy numbers (≥ 50 copies/mL).